General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis

News

Article

August 24, 2024

Derm In The News: August 18-24

Author(s):

Keep up with the latest headlines in dermatology from the past week, including the presence of toxic "forever chemicals" in artificial turf, commercial availability of apremilast in the US, and more.

KIMA: Toxic forever chemicals detected on kids' skin after playing on turf fields

New research has raised concerns about the presence of 'forever chemicals' (PFAS) on artificial turf fields, potentially posing health risks to children. A study by Public Employees for Environmental Responsibility found that kids playing on artificial turf fields had detectable levels of PFAS on their skin, which were not present after playing on natural grass fields. PFAS, linked to cancer and other health issues, are used in the production of artificial turf. Calls for action have intensified, with some states taking steps to restrict or ban PFAS in turf, while others have seen legislation vetoed.

Morningstar: Mollie Biggane Melanoma Foundation continues to fight skin cancer with their national outreach to firefighters

The Mollie Biggane Melanoma Foundation is expanding its efforts to combat skin cancer by targeting firefighters through a national outreach program. Recognizing the high risk of melanoma and other skin cancers among firefighters, the Foundation has partnered with fire departments to integrate skin cancer awareness into training programs. Initiatives include educational videos, sunscreen dispensers, and preventive posters at fire stations. Following successful implementation with the FDNY, the program has expanded to firefighter training communities in Warrensburg, Missouri, and Fairfax, Virginia.

Patient-Forward Rundown

Top headlines from this week to share with your patients:

PR Newswire: Otezela (apremilast) now available in the US for moderate to severe pediatric plaque psoriasis

Amgen announced that Otezla (apremilast) is now available in the US for pediatric use, following FDA approval for treating moderate to severe plaque psoriasis in children and adolescents aged 6 and older who weigh at least 20 kg. This makes Otezla the first FDA-approved oral medication for this condition in this age group. The approval is based on the Phase 3 SPROUT study, which demonstrated significant efficacy in reducing psoriasis symptoms compared to placebo.

Read more from Dermatology Times.

PR Newswire: Resivant Medical Receives FDA Clearance for Two Novel High-Viscosity Tissue Adhesive Products Cutiva Topical Skin Adhesive and Cutiva PLUS Skin Closure System

Resivant Medical has received FDA 510(k) clearance for its Cutiva Topical Skin Adhesive and Cutiva PLUS Skin Closure System. The Cutiva adhesive combines the strength of super glue with the flexibility of crosslinked silicone rubber, providing wound closure while reducing skin irritation. Cutiva PLUS integrates an adhesive mesh patch with the liquid adhesive, ensuring controlled application and easy removal.

BBC: Islands have 'high rate' of skin cancer - report

A recent study has revealed that skin cancer is the most common type of cancer in the Channel Islands, with about 40% of cancer cases being malignant skin cancers. This is notably higher compared to other regions of England, as found in an analysis by NHS England comparing cancer rates between 2005 and 2018.

Have you seen any dermatology headlines this week that we may have missed? Share with us by emailing our team at DTEditor@mmhgroup.com.